Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker.
about
Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipientsPre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving T-cell depleting induction therapyLong-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantationQuantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection.Endogenous memory CD8 T cells are activated within cardiac allografts without mediating rejection.Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeysVirtual Global Transplant Laboratory Standard Operating Protocol for Donor Alloantigen-specific Interferon-gamma ELISPOT AssayImmunologic monitoring in transplantation revisited.Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy.Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation.Immunologic monitoring in kidney transplant recipients.Memory T cells in organ transplantation: progress and challenges.Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.Monitoring alloimmune response in kidney transplantation.Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness.NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation.Posttransplant Immune Activation: Innocent Bystander or Insidious Culprit of Posttransplant Accelerated Atherosclerosis.Analysis of human biologics with a mouse skin transplant model in humanized mice.Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
P2860
Q33660602-A6A4321E-1951-4291-BFE6-ED5CB6100BCAQ35092328-6A40E649-EF07-4A23-97AA-7A7370D10B13Q35881889-F76A90A2-66C3-434C-AEED-18F1FD959533Q36200173-515AA7B7-A0DB-427B-A392-2812AE61EC89Q37179617-EAFE88B0-F54B-4223-8FD5-C3F1BD910814Q37362699-997C65C1-4786-4838-9802-6E3CC1634D02Q37394993-140A9208-0C04-419D-A504-E7111D79845BQ37970214-97AD6F2E-AC9A-46BD-9118-6882BB28B268Q38187176-46AEA38F-D107-406A-9456-37AFFE3C6DEAQ38202868-FE430A15-27A0-473E-B035-724B46286933Q38733824-C279BCF3-E347-48F3-8DE9-79466F396DAEQ38753494-74AE0EB1-B314-474A-B192-3A00F11E1BB9Q38773711-AD5D7B7B-C6E3-487A-93CC-01EF9AE61448Q38849321-003D9BFF-5650-4DDD-B0F5-351942BA5763Q39513891-55A91ED7-F261-4042-9E70-F1B64AD7F3EBQ40131984-2098A1C3-92A2-4820-B887-7705CC651EF4Q47119851-4F51D303-42D8-4397-958B-3F1763688D72Q50942355-8EBFCD9F-71FA-48BF-9C5A-190F97FFC24CQ52783253-F5AF9074-CC75-4B32-97B3-DE83398F197C
P2860
Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluation of alloreactivity i ...... versus IL-2 receptor blocker.
@ast
Evaluation of alloreactivity i ...... versus IL-2 receptor blocker.
@en
type
label
Evaluation of alloreactivity i ...... versus IL-2 receptor blocker.
@ast
Evaluation of alloreactivity i ...... versus IL-2 receptor blocker.
@en
prefLabel
Evaluation of alloreactivity i ...... versus IL-2 receptor blocker.
@ast
Evaluation of alloreactivity i ...... versus IL-2 receptor blocker.
@en
P2093
P2860
P1476
Evaluation of alloreactivity i ...... versus IL-2 receptor blocker.
@en
P2093
A Valujskikh
D A Shoskes
E D Poggio
L Cherkassky
L Danziger-Isakov
R L Fairchild
P2860
P304
P356
10.1111/J.1600-6143.2011.03540.X
P407
P577
2011-05-12T00:00:00Z